Intravitreal Therapeutics Utilization in 2023

Related

• 

  Endophthalmitis Rates of Prefilled Ranibizumab Syringes Compared to Conventional Ranibizumab Vials: An International Multicenter Study

  Yoshihiro Yonekawa, MD, FASRS

  Annual Meeting Talks

  2018

• 

  Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial

  Diana V Do, MD, FASRS

  Updates from the Field

  2024

• 

  Long-Term Outcome of Diabetic Eyes With Vitreous Hemorrhage in an Urban Safety-Net Hospital

  Hossein Ameri, MD, PhD, FRCSI, MRCOphth

  Annual Meeting Talks

  2024